Paraneoplastic Cerebellar Degeneration: When IVIG or Plasma Exchange Has Not Reduced Circulating Autoantibodies
This protocol addresses the management of rapidly progressive cerebellar syndrome in patients with confirmed antineuronal antibodies against intracellular antigens who have not achieved the required autoantibody reduction on initial immunotherapy.
Clinical Scenario
Rapidly progressive cerebellar syndrome with detected antineuronal antibodies directed against intracellular antigens. This antibody subtype has distinct immunological characteristics — specifically, regimens targeting T-cell-based mechanisms are considered to hold an advantage compared with approaches focused on B-cells alone.
Prior Line — Insufficient Response
Initial immunotherapy with intravenous immunoglobulins (IVIG) or plasma exchange (PLEX) — given alongside corticosteroids for severe or rapidly worsening presentations, or as second-line after corticosteroid monotherapy — did not achieve the key goal: reduction of circulating autoantibodies. This protocol defines the next management step following that failure.
Next Treatment Approach (Partial Overview)
The escalated approach centres on maintenance immunotherapy with immunosuppressants that broadly target immune cell populations, with particular emphasis on T-cell-based mechanisms — the rationale being that B-cell-only strategies are generally considered less effective in the setting of antibodies directed against intracellular antigens.
Specific agents, selection criteria, sequencing, and contingency options are detailed in the full protocol.
References
DOI: 10.3390/brainsci11111414
- If a specific antibody has been detected, one can distinguish between antibodies directed against intracellular antigens and antibodies directed against cell-surface antigens.
- In the first case, regimens targeting T-cell based mechanisms might be of advantage.
- Therefore, regimens targeting B-cells alone (e.g., anti-CD20 antibody rituximab) might not be as effective in these cases.
View source ↗